BR112013018951B1 - Formulações transdérmicas ou transmucosais de testosterona e seu uso e kit que compreende pelo menos um recipiente que compreende uma formulação - Google Patents

Formulações transdérmicas ou transmucosais de testosterona e seu uso e kit que compreende pelo menos um recipiente que compreende uma formulação Download PDF

Info

Publication number
BR112013018951B1
BR112013018951B1 BR112013018951-7A BR112013018951A BR112013018951B1 BR 112013018951 B1 BR112013018951 B1 BR 112013018951B1 BR 112013018951 A BR112013018951 A BR 112013018951A BR 112013018951 B1 BR112013018951 B1 BR 112013018951B1
Authority
BR
Brazil
Prior art keywords
weight
testosterone
formulation
amount
gel
Prior art date
Application number
BR112013018951-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013018951A2 (pt
Inventor
Arnaud Grenier
Dario N. Carrara
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013018951(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of BR112013018951A2 publication Critical patent/BR112013018951A2/pt
Publication of BR112013018951B1 publication Critical patent/BR112013018951B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112013018951-7A 2011-01-26 2012-01-18 Formulações transdérmicas ou transmucosais de testosterona e seu uso e kit que compreende pelo menos um recipiente que compreende uma formulação BR112013018951B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161436207P 2011-01-26 2011-01-26
US61/436,207 2011-01-26
EP11152210 2011-01-26
EP11152210.8 2011-01-26
PCT/EP2012/050695 WO2012101016A1 (en) 2011-01-26 2012-01-18 Testosterone formulations

Publications (2)

Publication Number Publication Date
BR112013018951A2 BR112013018951A2 (pt) 2017-04-04
BR112013018951B1 true BR112013018951B1 (pt) 2020-03-10

Family

ID=44146428

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018951-7A BR112013018951B1 (pt) 2011-01-26 2012-01-18 Formulações transdérmicas ou transmucosais de testosterona e seu uso e kit que compreende pelo menos um recipiente que compreende uma formulação

Country Status (28)

Country Link
US (2) US8895053B2 (enExample)
EP (2) EP3072505B1 (enExample)
JP (2) JP6012632B2 (enExample)
KR (1) KR101877476B1 (enExample)
CN (1) CN103327962B (enExample)
AR (1) AR085090A1 (enExample)
AU (1) AU2012210691B2 (enExample)
BR (1) BR112013018951B1 (enExample)
CA (1) CA2824941A1 (enExample)
DK (2) DK2667851T3 (enExample)
ES (2) ES2586122T3 (enExample)
HR (2) HRP20160887T1 (enExample)
HU (3) HUE044327T2 (enExample)
IL (1) IL227454A (enExample)
JO (1) JO3755B1 (enExample)
LT (2) LT3072505T (enExample)
MX (1) MX340259B (enExample)
NO (1) NO2018034I1 (enExample)
PL (2) PL3072505T3 (enExample)
PT (2) PT2667851T (enExample)
RS (2) RS54898B1 (enExample)
RU (1) RU2613891C2 (enExample)
SA (1) SA112330224B1 (enExample)
SI (2) SI2667851T1 (enExample)
TR (1) TR201909271T4 (enExample)
TW (1) TWI564029B (enExample)
WO (1) WO2012101016A1 (enExample)
ZA (1) ZA201305665B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
AU2010243273B2 (en) * 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
RS55457B1 (sr) 2010-10-27 2017-04-28 Ferring Bv Postupak za proizvodnju degareliksa i njegovih intermedijara
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix
US8785426B1 (en) * 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
JP6444956B2 (ja) * 2015-09-30 2018-12-26 富士フイルム株式会社 経皮吸収用組成物
TWI857942B (zh) * 2017-10-30 2024-10-11 日商帝國製藥股份有限公司 經皮投與製劑
US11523994B2 (en) 2018-01-10 2022-12-13 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
WO2020010205A1 (en) 2018-07-05 2020-01-09 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
CN109700764B (zh) * 2019-02-20 2021-07-06 广东食品药品职业学院 双氢睾酮原位凝胶喷雾剂及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2862341D1 (en) 1977-12-26 1983-11-24 Ihara Chemical Ind Co Process for producing aromatic monocarboxylic acid
JP2719233B2 (ja) 1991-04-25 1998-02-25 デゲンギ，ロマノ 黄体形成ホルモン放出ホルモン拮抗ペプチド
DK0556034T4 (da) 1992-02-12 2004-11-15 Daikyo Gomu Seiko Kk Et medicinsk instrument
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
CN1997357A (zh) * 2003-03-11 2007-07-11 安塔雷斯制药Ipl股份公司 透皮或透粘膜应用活性剂的用途和制剂
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
PT1670433E (pt) * 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
MX2007015255A (es) * 2005-06-03 2008-02-22 Acrux Dds Pty Ltd Metodo y composicion para administracion transdermica de un farmaco.
NZ571460A (en) * 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
CN101754764A (zh) * 2007-03-23 2010-06-23 优尼麦德药物股份有限公司 治疗小儿性腺机能减退的组合物和方法
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
ES2589322T3 (es) 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
AU2010243273B2 (en) 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2012024361A1 (en) * 2010-08-17 2012-02-23 Biosante Pharmaceuticals, Inc. Commercial scale production methods for transdermal hormone formulations
RS55457B1 (sr) 2010-10-27 2017-04-28 Ferring Bv Postupak za proizvodnju degareliksa i njegovih intermedijara
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013012783A1 (en) 2011-07-15 2013-01-24 Joseph Raymond E Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
HUE027453T4 (hu) 2018-12-28
US20130295166A1 (en) 2013-11-07
US8895053B2 (en) 2014-11-25
AU2012210691B2 (en) 2016-05-12
AR085090A1 (es) 2013-09-11
MX340259B (es) 2016-07-04
TW201309341A (zh) 2013-03-01
IL227454A (en) 2017-02-28
HUE027453T2 (en) 2016-09-28
TR201909271T4 (tr) 2019-07-22
EP2667851A1 (en) 2013-12-04
JP2014503565A (ja) 2014-02-13
RS54898B1 (sr) 2016-10-31
JP6012632B2 (ja) 2016-10-25
CN103327962A (zh) 2013-09-25
AU2012210691A1 (en) 2013-08-01
WO2012101016A1 (en) 2012-08-02
HUE044327T2 (hu) 2019-10-28
ES2741744T3 (es) 2020-02-12
CA2824941A1 (en) 2012-08-02
KR20140041431A (ko) 2014-04-04
PT3072505T (pt) 2019-07-04
EP3072505B1 (en) 2019-06-12
ES2586122T3 (es) 2016-10-11
EP3072505A1 (en) 2016-09-28
SI2667851T1 (sl) 2016-07-29
US20150110856A1 (en) 2015-04-23
JP2017019819A (ja) 2017-01-26
PL3072505T3 (pl) 2019-12-31
IL227454A0 (en) 2013-09-30
LTPA2018516I1 (lt) 2018-11-12
ZA201305665B (en) 2014-03-26
JO3755B1 (ar) 2021-01-31
PT2667851T (pt) 2016-07-26
SI3072505T1 (sl) 2019-08-30
BR112013018951A2 (pt) 2017-04-04
HRP20191216T1 (hr) 2019-10-18
HK1192719A1 (zh) 2014-08-29
RU2013133082A (ru) 2015-03-10
PL2667851T3 (pl) 2017-01-31
MX2013008463A (es) 2013-10-03
CN103327962B (zh) 2016-04-27
NZ613029A (en) 2014-03-28
KR101877476B1 (ko) 2018-07-11
DK2667851T3 (en) 2016-07-25
RS59012B1 (sr) 2019-08-30
EP2667851B1 (en) 2016-05-18
NO2018034I1 (no) 2018-09-27
SA112330224B1 (ar) 2015-02-22
LT3072505T (lt) 2019-08-26
RU2613891C2 (ru) 2017-03-21
HUS1800036I1 (hu) 2018-09-28
HRP20160887T1 (hr) 2016-09-23
TWI564029B (zh) 2017-01-01
DK3072505T3 (da) 2019-08-12

Similar Documents

Publication Publication Date Title
AU2012210691B2 (en) Testosterone formulations
JP4825305B2 (ja) 経皮吸収製剤
US20110195114A1 (en) Transdermal delivery systems for active agents
BRPI1001367A2 (pt) composição para aplicação tópica
PT1322336E (pt) Método de aumentar as concentrações de testosterona e esteróides relacionados em mulheres
ES2548723T3 (es) Geles a base de testosterona que comprenden propilenglicol y miristato de isopropilo como promotores de penetración
CA2623477C (en) Compositions and method for treating pediatric hypogonadism
NZ613029B (en) Testosterone formulations
HK1227768B (en) Testosterone formulations
HK1227768A1 (en) Testosterone formulations
HK1227768A (en) Testosterone formulations
HK1192719B (en) Testosterone formulations
BRPI0515040B1 (pt) Géis de testosterona compreendendo propileno glicol como intensificador de penetração
KR100871531B1 (ko) 테스토스테론 외용제
HK1099887B (en) Testosterone gels comprising propylene glycol and isopropyl myristate as penetration enhancers

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/01/2012, OBSERVADAS AS CONDICOES LEGAIS.